Table 1.
Current clinical trials combining checkpoint inhibitors and epigenetic drugs in different solid tumor types
| ClinicalTrials.gov identifier | Recruiment status | Phase | Cancer type | Epigenetic drug/s | Epigenetic target | Immune checkpoint inhibitor/s |
|---|---|---|---|---|---|---|
| NCT02437136 | Active, not recruiting | 1a/b | NSCLC, melanoma and mismatch repair-proficient CRC | Entinostat | HDAC1,2,3 | Pembrolizumab |
| NCT02638090 | Recruiting | 1/2 | Stage IV NSCLC | Vorinostat | HDAC1,2,3,7,11 | Pembrolizumab |
| NCT02512172 | Active, not recruiting | 1 | MSS CRC | Romidepsin, oral azacitidine | HDAC1,2; DNMT1 | Pembrolizumab |
| NCT03264404 | Recruiting | 2 | PDA | Azacitidine | DNMT1 | Pembrolizumab |
| NCT03854474 | Recruiting | 1/2 | Advanced urothelial carcinoma, locally advanced urothelial carcinoma, metastatic bladder urothelial carcinoma | Tazemetostat | EZH2 | Pembrolizumab |
| NCT03590054 | Recruiting | 1 | Stage III cutaneous melanoma, stage IV cutaneous melanoma, locally advanced melanoma, locally advanced solid neoplasm | Abexinostat | Pan-HDAC inhibitor | Pembrolizumab |
| NCT03250273 | Recruiting | 2 | PDA and cholangiocarcinoma | Entinostat | HDAC1,2,3 | Nivolumab |
| NCT01928576 | Recruiting | 2 | NSCLC | Azacitidine with/without entinostat | DNMT1; HDAC1,2,3 | Nivolumab |
| NCT02635061 | Active, not recruiting | 1 | NSCLC | ACY-421 | HDAC6 | Nivolumab |
| NCT02032810 | Active, not recruiting | 1 | Unresectbale III/IV melanoma | Panobinostat | HDAC | Ipilimumab |
| NCT02708680 | Active, not recruiting | 1b | TNBC | Entinostat | HDAC1,2,3 | Atezolizumab |
| NCT02805660 | Active, not recruiting | 1/2 | Advanced solid tumors and NSCLC | Mecotinostat | HDAC1,2,3,11 | Durvalumab |
| NCT03308396 | Recruiting | 1/2 | Advanced kidney cancer, renal cell cancer | Guadecitabine | DNMT1 | Durvalumab |
| NCT02915523 | Active, not recruiting | 1b/2 | Advanced epithelial OC | Entinostat | HDAC1,2,3 | Avelumab |
| NCT03812796 | Recruiting | 2 | GI cancer | Domatinostat | HDAC1,2,3 | Avelumab |
| NCT02961101 | Recruiting | 1/2 | Non-Hodgkins lymphoma, Hodgkins lymphoma, GI cancer, HPC, BC, OC, lung cancer, renal cell cancer, PDA, bile duct cancer | Decitabine | DNMT1, DNMT3A, DNMT3B | Anti-PD-1 antibody |
All information on current clinical trials was obtained from ClinicalTrials.gov
NSCLC non-small cell lung cancer, BC breast cancer, OC ovarian cancer, MSS microsatellite stable, CRC colorectal cancer, TNBC triple-negative breast cancer, GI gastrointestinal, PDA pancreatic ductal adenocarcinoma